Natural Killer Cell KIR and HLA Genotypes May Predict Response to Antibody Therapy in Follicular Lymphoma
- To test the hypothesis that killer immunoglobulin-like receptor (KIR) and HLA genotypes
predict 12-month overall response (complete response, partial response, and unconfirmed
complete response) in patients with follicular lymphoma treated with
rituximab-containing monoclonal antibody combinations on CALGB-50402 or CALGB-50701.
- To test the hypothesis that KIR and HLA genotypes are associated with survival outcomes
(progression-free and overall survival) in these patients.
OUTLINE: This is a multicenter study.
Genomic DNA is extracted from previously collected whole blood samples for killer
immunoglobulin-like receptor (KIR) and HLA genotyping and polymorphism analysis.
Association between killer immunoglobulin-like receptor (KIR) and HLA genotypes and 12-month overall response
Jeffrey M. Venstrom, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government